Translational Drug Development (TD2)
Caroline Nehme, M.S., is a Senior Clinical Data Associate at Translational Drug Development (TD2) since July 2023, with extensive experience in clinical data management. Previously at Seagen through ICON plc, Caroline supported oncology studies by compiling data and streamlining processes to enhance efficiency. Prior roles include Senior Clinical Data Coordinator at ICON plc, Clinical Data Coordinator at ICON Government and Public Health Solutions, and a Clinical Trial Customer Service Representative at Cenduit. Earlier experience also includes a Researcher/Marketing Specialist position at Integrity Personnel, Inc. and a Research Assistant role at Lehigh University. Caroline holds a Master of Science in Clinical Research Organization and Management from Drexel University College of Medicine and a Bachelor of Science in Neuroscience from Moravian University.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.